

Cancer **C**hemotherapy and **P**armacology

Volume 25 1989/90

Edited by

A. H. CALVERT, S. K. CARTER, M. J. EGORIN, D. R. NEWELL

Editorial Board

P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
R. L. Comis Philadelphia
T. Connors Carshalton
R. C. Coombes Sutton
M. d'Incalci Milan
C. Dittrich Vienna
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Victoria
S. Garattini Milano

A. Gouyette Villejuif
H. H. Hansen Copenhagen
A. Jeney Budapest
R. B. Livingston Seattle
J. S. Macdonald Lexington
T. J. McElwain Sutton
J. G. McVie London
F. M. Muggia Los Angeles
M. Ogawa Tokyo
G. Powis Rochester
M. Rozenzweig Brussels
C. G. Schmidt Essen

H. J. Senn St. Gallen
C. Sessa Bellinzona
J. F. Smyth Edinburgh
S. Tsukagoshi Tokyo
T. Tsuruo Tokyo
F. A. Valeriote Detroit
L. M. van Putten Rijswijk
P. M. Wilkinson Manchester
P. Workman Cambridge
G. Wu Huan-Hsin Beijing



Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Founding editor: G. Mathé.

Editors: S. K. Carter, T. J. McElwain. As of volume 23 (1989): S. K. Carter, A. H. Calvert. As of volume 24 (1989): A. H. Calvert, S. K. Carter, M. J. Egorin.

Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäss bei Augsburg

© Springer-Verlag Berlin Heidelberg 1990

Contents of volume 25

No. 1 (pp 1-76) published 13 October 1989
 No. 2 (pp 77-148) published 24 October 1989
 No. 3 (pp 149-226) published 13 November 1989
 No. 4 (pp 227-310) published 27 December 1989
 No. 5 (pp 311-388) published 9 February 1990
 No. 6 (pp 389-464) published 26 February 1990

Abildgaard U → Daugaard G

Aghai E, Tökés ZA: Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells 295

Alaoui Jamali MA, Yin M-b, Mazzoni A, Bankusli I, Rustum YM: Relationship between cytotoxicity drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933 77

Alberts DS → Xu M-J

Alberts DS → Buzaid AC

Andrews PA → Mann SC

Arakali AV → Pendyala L

Archimbaum E, Troncy J, Sebban C,

Guyotat D, Devaux Y, French M, Moriceau M, Viala J-J, Fiere D: Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 223

Atassi G, Dumont P, Gosse C, Fournier JP, Gouyette A, Roger P: Characterization of the anti-tumor activity against solid tumours of a new nitrosourea sugar: Cy 233 205

Audhuy B → Jacquillat C

Avramis VI, Powell WC, Mecum RA: Cellular metabolism of 1-β-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells 19

Avril M-F → Jacquillat C

Bagshawe KD → Smith DB

Baker R → Radel S

Baldew GS → Los G

Ball D → Bishop JF

Bankusli I → Alaoui Jamali MA

Banzet P → Jacquillat C

Beattie G, Whelan J, Cassidy J, Milne L, Burns S, Leonard R: Herpes simplex virus, *Candida albicans* and mouth ulcers in neutropenic patients with non-haematological malignancy 75

Begent RHJ → Smith DB

Belvedere G → Capolongo L

Benjamin LA, McGarry RC, Hart DA: Effect of retinoic acid on human neuroblastoma. Correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity 25

Benz CC → Wiebe VJ

Berendsen HH → Smit EF

Bernardini M → Danesi R

Bernardini N → Danesi R

Beynen JH → Vlasveld LT

Bibby MC → Masters JRW

Bishop JF → Reece PA

Bishop JF, Kefford R, Raghavan D, Zalberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K, Matthews JP, Zimet A: Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer 367

Bizzari J-P → Jacquillat C

Bizzari JP → Fischel JL

Blackledge GRP → Kerr DJ

Boas J, Rasmussen D, Hansen OP, Engelholm SA, Dombernowsky P: Phase II study of teniposide in advanced breast cancer 463

Bohm S → Di Re F

Bonerandi J-J → Jacquillat C

Bonnetterre J → Jacquillat C

Boogerd W → Vlasveld LT

Boschelli D → Ferguson K

Bradley C → Kerr DJ

Braine HG → Grochow LB

Brann TW → Rosbe KW

Breau A → Chapman DE

Bronchud MH, Margison JM, Howell A, Lind M, Lucas SB, Wilkinson PM: Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer 435

Brundrett RB → Grochow LB

Bugat R → Jacquillat C

Bull C → Bishop JF

Burns S → Beattie G

Burton EC → Maybaum J

Butcher ME → Viner CV

Buzaid AC, Alberts DS, Einspahr J, Mosley K, Peng Y-M, Tutsch K, Spears CP, Garewal HS: Effect of dipyrindamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients 124

Cadman TB → Wiebe VJ

Calvo F → Extra JM

Capizzi RL → Wang LM

Capolongo L, Belvedere G, D'Incalci M: DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells 430

Carruthers L → Smith DB

Cassidy J → Beattie G

Cerny T → Lind MJ

Chaney S → Rosenblum MG

Chapman DE, Moore DJ, Melder DC, Breau A, Powis G: Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma 184

Chaudary MA → Twelves CJ

Chen T-L → Grochow LB

Cheshire P → Houghton PJ

Christensen B → Ueland PM

Clagett-Carr K → Foster BJ

Cleary SM → Kirmani S

Clemens MR → Ladner C

Coleman RE → O'Reilly SM

Colvin OM → Grochow LB

Cowens JW → Pendyala L

Crawford SM → Smith DB

Creaven PJ → Pendyala L

Crespeigne N → Schwartzmann G

Cupissol D → Jacquillat C

Currie DC, Miles DW, Drake JS, Rudd R, Spiro SG, Earl HM, Harper PG, Tobias JS, Souhami RL: Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer 380

Daly EM → Greig NH

Danesi R, Bernardini N, Marchetti A, Bernardini M, Del Tacca M: Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats 326

Daugaard G, Abildgaard U: Cisplatin nephrotoxicity. A review 1

Deeb G → Gaver RC

DeGregorio MW → Wiebe VJ

Deloffre P → Fischel JL

Del Tacca M → Danesi R

Devaux Y → Archimbaud E

Dijk A v → Zonnenberg BA

D'Incalci M → Capolongo L

D'Incalci M → Zanette L

Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F: Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer 355

Di Salle E → Zaccaro T

Dive C, Workman P, Watson JV: Inhibition of cellular esterases by the antitumour imidazotetrazines mitoxantrone and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry 149

Dodion P → Schwartzmann G

Dolan ME, Larkin GI, English HF, Pegg AE: Depletion of O⁶-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O⁶-methylguanine 103

Dombernowsky P → Boas J

Dopfer R → Klingebiel T

Drake JS → Currie DC

Dumont P → Atassi G

Durr FE → Wallace RE

Dykes DJ → Harrison SD Jr

Earl HM → Currie DC

Eder JP → Teicher BA

Egami K → Yoshida T

Ehninger G → Klingebiel T

Ehninger G → Ladner C

Einspahr J → Buzaid AC

Engelholm SA → Boas J

English HF → Dolan ME

Ensminger WD → Maybaum J

Erranti D → Zanette L

Espie M → Extra JM

Etienne MC → Fischel JL

- Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer 299
- Farnworth P, Hillcoat B, Roos I: Metallothionein-like proteins and cell resistance to *cis*-dichloro-diammineplatinum(II) in L1210 cells 411
- Feine U → Klingebiel T
- Fenwick E → Masters JRW
- Ferguson K, Boschelli D, Hoffman P, Oronsky A, Whiteley J, Webber S, Galivan J, Freishiem J, Hynes J, Kerwar SS: Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors 173
- Ferme C → Extra JM
- Fiere D → Archimbaud E
- Fischel JL, Formento P, Etienne MC, Gioanni J, Frenay M, Deloffre P, Bizzari JP, Milano G: In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea 337
- Formento P → Fischel JL
- Foster BJ, Harding BJ, Wolpert-DeFilippes MK, Rubinstein LY, Clagett-Carr K, Leyland-Jones B: A strategy for the development of two clinically active cisplatin analogs: CBDCa and CHIP 395
- Fournier JP → Atassi G
- Fredericks W → Radel S
- Frei E III → Rosbe KW
- Freishiem J → Ferguson K
- Frenay M → Fischel JL
- French BT → Gibboney DS
- French M → Archimbaud E
- Freshi A → Zanette L
- Friedlander M → Bishop JF
- Fuchs D → Reibnegger G
- Fumoleau P → Jacquillat C
- Galivan J → Ferguson K
- Gall H → Schwartzmann G
- Garewal HS → Buzaid AC
- Gaver RC, Deeb G, George AM: Validated HPLC procedures for the analysis of BMV-28090 in human plasma and urine 195
- Genka S → Greig NH
- George AM → Gaver RC
- George WD → Stallard S
- Gey KF → Ladner C
- Gibboney DS, French BT, Patrick DE, Trewyn RW: 6-Ethylmercaptapurine-mediated growth inhibition of HL-60 cells in vitro irrespective of purine salvage 189
- Gioanni J → Fischel JL
- Goddard PM, Jones M, Pollard LA, Valenti MR, Harrap KR: The 5-HT₁ antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice 377
- Goel R, Sanga R, Howell SB: Pharmacologic basis for the use of dihydropyridine to increase the selectivity of intraperitoneally delivered methotrexate 167
- Goldstone A → Twelves C
- Goodman G → Mortimer JE
- Gore ME → Viner CV
- Goren MP, Pratt CB, Viar MJ: Tubular nephrotoxicity during long-term ifosfamide and mesna therapy 70
- Goren MP, Pratt CB: False-positive ketone tests: a bedside measure of urinary mesna 371
- Gosse C → Atassi G
- Gouyette A → Atassi G
- Greenhalgh DA, Parish JH: Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells 37
- Greig NH, Daly EM, Genka S, Sweeney DJ, Rapoport SI: Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration 311
- Greig NH, Daly EM, Sweeney DJ, Rapoport SI: Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain 320
- Grindey GB → Houghton PJ
- Griswold DP Jr → Harrison SD Jr
- Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation 55
- Grosshans E → Jacquillat C
- Grunberg SM, Sonka S, Stevenson LL, Muggia FM: Progressive paresthesias after cessation of therapy with very high-dose cisplatin 62
- Guentert TW → Reece PA
- Guyotat D → Archimbaud E
- Hafner MS → Maybaum J
- Hagen B, Neverdal G, Walstad RA, Nilsen OG: Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i. v. bolus administration of thio-TEPA in ovarian cancer patients 257
- Hansen OP → Boas J
- Harding BJ → Foster BJ
- Harper P → Twelves C
- Harper PG → Currie DC
- Harrap KR → Goddard PM
- Harrison SD Jr, Plowman J, Dykes DJ, Waud WR, Griswold DP Jr: Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo 425
- Hart DA → Benjamin LA
- Hausen A → Reibnegger G
- Hejl M → Schmiegelow K
- Hennik MB van → Schwartzmann G
- Herman TS → Teicher BA
- Hilgard P → Stekar J
- Hillcoat B → Farnworth P
- Hillcoat BL → Reece PA
- Hill HS → Reece PA
- Hoesel QGCM van → Wagener DJT
- Hoffman P → Ferguson K
- Holden SA → Rosbe KW
- Holden SA → Teicher BA
- Holtei W → Stekar J
- Hoogenraad WJ → Wagener DJT
- Houghton JA → Houghton PJ
- Houghton PJ, Houghton JA, Myers L, Cheshire P, Howbert JJ, Grindey GB: Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma 84
- Howbert JJ → Houghton PJ
- Howell A → Bronchud MH
- Howell SB → Goel R
- Howell SB → Mann SC
- Howell SB → Kirmani S
- Hynes J → Ferguson K
- Israel M, Sweatman TW, Seshadri R, Koseki Y: Comparative uptake and retention of adriamycin and N-benzyl-adriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures 177
- Jacquillat C, Khayat D, Banzet P, Weil M, Avril M-F, Fumoleau P, Namer M, Bonnetterre J, Kerbrat P, Bonerandi J-J, Bugat R, Montcuquet P, Audhuy B, Cupissol D, Lauvin R, Grosshans E, Vilmer C, Prache C, Bizzari J-P: Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma 263
- James N → Waxman J
- Jenkins WEA → Masters JRW
- Joggi J → Schwartzmann G
- Jones M → Goddard PM
- Jones RJ → Grochow LB
- Jones SM → Teicher BA
- Kanai M → Yoshida T
- Kanno M → Yoshida T
- Kaye SB → Stallard S
- Kaye SB → Kerr DJ
- Kefford R → Bishop JF
- Keller KD → Klingebiel T
- Kerbrat P → Jacquillat C
- Kerr DJ, Slack JA, Secrett P, Stevens MFG, Blackledge GRP, Bradley C, Kaye SB: Relationship between the pharmacokinetics and toxicity of mitozolomide 352
- Kerwar SS → Ferguson K
- Khayat D → Jacquillat C
- Khokhar AR → Rosenblum MG
- Kim GE, Song CW: The influence of Fluorolone and carbogen breathing on the antitumor effects of cyclophosphamide in vivo 99
- Kirmani S, Zimm S, Cleary SM, Mowry J, Howell SB: Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside 454
- Klingebiel T, Treuner J, Ehninger G, Keller KD, Dopfer R, Feine U, Niethammer D: [¹³I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects 143
- Kobayashi K → Yoshida T
- Kondo K → Yoshida T
- Kopecny K → Mortimer JE
- Koseki Y → Israel M
- Kramer RA → Nakagawa Y

- Kramer RA: Protection against cisplatin nephrotoxicity by prochlorperazine 156
- Krishnan BS → Pendyala L
- Kühl M → Schalhorn A
- Ladner C, Ehninger G, Gey KF, Clemens MR: Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen 210
- Larkin GI → Dolan ME
- Larson RE → Stolzenbach JC
- Lauvin R → Jacquillat C
- Leibovitz A → Xu M-J
- Lenglet WJM → Los G
- Leonard R → Beattie G
- Leyland-Jones B → Foster BJ
- Liliemark J → Sundman-Engberg B
- Lindh D → Wallace RE
- Lind M → Bronchud MH
- Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution 139
- Liu R → Xu M-J
- Liu Y → Xu M-J
- Loadman PM → Masters JRW
- Los G, Mutsaers PHA, Lenglet WJM, Baldew GS, McVie JG: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment 389
- Lucas SB → Bronchud MH
- MacDonald JS → Mortimer JE
- Malatesta V → Monti E
- Mann SC, Andrews PA, Howell SB: Short-term *cis*-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells 236
- Marchetti A → Danesi R
- Margison JM → Lind MJ
- Margison JM → Bronchud MH
- Marty M → Extra JM
- Masters JRW, McDermott BJ, Jenkins WEA, Fenwick E, Shah PJR, Mundy AR, Loadman PM, Bibby MC: ThioTEPA pharmacokinetics during intravenous chemotherapy and the influence of Tween 80 267
- Matano S → Yoshida T
- Matsuda T → Yoshida T
- Matthews JP → Bishop JF
- Maybaum J, Hafner MS, Burton EC, Stetson PL, Ensminger WD, Rogers CE: Response of human HT-29 colorectal tumor cells to extended exposure to bromodeoxyuridine 45
- Mayhew E → Radel S
- Mazzoni A → Alaoui Jamali MA
- McDermott BJ → Masters JRW
- McElwain TJ → Viner CV
- McGarry RC → Benjamin LA
- McVie JG → Los G
- Mecum RA → Avramis VI
- Melder DC → Chapman DE
- Mignot L → Extra JM
- Milano G → Fischel JL
- Miles DW → Currie DC
- Miller AA, Stewart CF, Tolley EA: Clinical pharmacodynamics of continuous-infusion etoposide 361
- Milne L → Beattie G
- Momparler LF → Momparler RL
- Momparler RL, Momparler LF: Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine 51
- Montcuquet R → Jacquillat C
- Monti E, Paracchini L, Piccinini F, Malatesta V, Morazzoni F, Supino R: Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate 333
- Moore DJ → Chapman DE
- Morazzoni F → Monti E
- Moriceau M → Archimbaud E
- Morrison JG → Stallard S
- Morris RG → Reece PA
- Mortimer JE, Schulman S, MacDonald JS, Kopecky K, Goodman G: High-dose cisplatin in disseminated melanoma: a comparison of two schedules 373
- Mosley K → Buzaid AC
- Mowry J → Kirmani S
- Muggia FM → Grunberg SM
- Mulder NH → Smit EF
- Mundy AR → Masters JRW
- Murray JL → Rosenblum MG
- Mutsaers PHA → Los G
- Myers L → Houghton PJ
- Nakagawa Y, Kramer RA: Nephrotoxicity of 5-(N-phenylcarboxamido)-2-thiobarbituric acid in the Fischer 344 rat 109
- Nakamura S → Yoshida T
- Namer M → Jacquillat C
- Natori H → Yoshida T
- Neverdal G → Hagen B
- Neville AJ, Singh G: Effect of whole-body hyperthermia on hepatic cytochrome P450 342
- Newlands ES → Smith DB
- Newman RA → Rosenblum MG
- Niethammer D → Klingebiel T
- Nilsen OG → Hagen B
- Nüssler V → Schalhorn A
- Ohtake S → Yoshida T
- Okafuji K → Yoshida T
- Oliver IN → Reece PA
- Oliver IN → Bishop JF
- O'Reilly SM, Coleman RE, Rubens RD: Phase II study of mitoxantrone for liver metastases from breast cancer 73
- Oriana S → Di Re F
- Oronsky A → Ferguson K
- Paracchini L → Monti E
- Parish JH → Greenhalgh DA
- Parodi MT, Varesio L, Tonini GP: Morphological change and cellular differentiation induced by cisplatin in human neuroblastoma cell lines 114
- Patrick DE → Gibboney DS
- Paul C → Sundman-Engberg B
- Pawlicki M, Zuchowska-Vogelsang B, Sliz E: The case of Vepesid overdosage in a patient with Hodgkin's disease 387
- Pegg AE → Dolan ME
- Pendyala L, Krishnan BS, Walsh JR, Arakali AV, Cowens JW, Creaven PJ: Studies on the human metabolism of iproplatin 10
- Pendyala L, Walsh JR, Huq MM, Arakali AV, Cowens JW, Creaven PJ: Uptake and metabolism of iproplatin in murine L1210 cells 15
- Peng Y-M → Buzaid AC
- Piccinini F → Monti E
- Pinedo HM → Schwartzmann G
- Plowman J → Harrison SD Jr
- Pollard LA → Goddard PM
- Postmus PE → Smit EF
- Powell WC → Avramis VI
- Powis G → Chapman DE
- Prache C → Jacquillat C
- Pratt CB → Goren MP
- Pratt CB → Goren MP
- Pulczynska MK → Schmiegelow K
- Radel S, Fredericks W, Mayhew E, Baker R: P-Glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells 241
- Raghavan D → Bishop JF
- Rapoport SI → Greig NH
- Rasmussen D → Boas J
- Reece PA, Oliver IN, Morris RG, Bishop JF, Guentert TW, Hill HS, Hillcoat BL: Pharmacokinetic study of doxiluridine given by 5-day stepped-dose infusion 274
- Refsum H → Ueland PM
- Reibnegger G, Fuchs D, Hausen A, Werner ER, Werner-Felmayer G, Wachter H: Unconjugated pteridines and the activation of macrophages by interferon gamma 308
- Reidy J → Twelves CJ
- Richards MA → Twelves CJ
- Riemer U → Stekar J
- Rodenhuis S → Vlasveld LT
- Roger P → Atassi G
- Rogers CE → Maybaum J
- Roos I → Farnworth P
- Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E III: Effect of Ionidamine on the cytotoxicity of four alkylating agents in vitro 32
- Rosenblum MG, Murray JL, Stuckey S, Newman RA, Chaney S, Khokhar AR: Modification of methyliminodiacetate-*trans*-R,R-1,2-diamminocyclohexane platinum (II) pharmacology using a platinum-specific monoclonal antibody 405
- Rubens RD → O'Reilly SM
- Rubens RD → Twelves CJ
- Rubinstein LY → Foster BJ
- Rudd R → Currie DC
- Rustin GJS → Smith DB
- Rustum YM → Alaoui Jamali MA
- Sandow J → Waxman J
- Sanga R → Goel R
- Santos GW → Grochow LB
- Saral R → Grochow LB
- Sava G: Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 221
- Schalhorn A, Kühl M, Stupp-Poutot G, Nüssler V: Pharmacokinetics of reduced folates after short-term infusion of d,l-folinic acid 440
- Schmiegelow K, Schröder H, Pulczynska MK, Hejl M: Maintenance chemotherapy

- apy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes 65
- Schornagel JH → Zonnenberg BA
- Schroder H → Schmiegelow K
- Schulman S → Mortimer JE
- Schwartzmann G, Dodion P, Vermorken JB, Ten Bokkel Huinink WW, Joggi J, Winograd B, Gall H, Simonetti G, Vijgh WJF van der, Hennik MB van, Crespeigne N, Pinedo HM: Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies 345
- Sebban C → Archimbaud E
- Secrett P → Kerr DJ
- Selby PJ → Viner CV
- Seshadri R → Israel M
- Shah PJR → Masters JRW
- Shemano I → Wiebe VJ
- Simonetti G → Schwartzmann G
- Singh G → Neville AJ
- Slack JA → Kerr DJ
- Sliz E → Pawlicki M
- Smit EF, Berendsen HH, Vries EGE de, Mulder NH, Postmus PE: A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer 202
- Smith DB, Newlands ES, Rustin GJS, Begent RHJ, Crawford SM, Bagshawe KD, Carruthers L: A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy 291
- Song CW → Kim GE
- Sonka S → Grunberg SM
- Souhami R → Twelves C
- Souhami RL → Currie DC
- Spatti GB → Di Re F
- Spears CP → Buzaid AC
- Spiro SG → Currie DC
- Stallard S, Morrison JG, George WD, Kaye SB: Distribution of doxorubicin to normal breast and tumor tissue in patients undergoing mastectomy 286
- Stekar J, Hilgard P, Holtei W, Riemer U: Protection from ifosfamide-induced alopecia by topical thiols in young rats 306
- Stetson PL → Maybaum J
- Stevens MFG → Kerr DJ
- Stevenson LL → Grunberg SM
- Stewart CF → Miller AA
- Stolzenbach JC, Larson RE: BCNU-induced quantitative and qualitative changes in hepatic cytochrome P-450 can be correlated with cholestasis 227
- Strijk SP → Wagener DJT
- Struyvenberg A → Zonnenberg BA
- Stuart-Harris R → Bishop JF
- Stuckey S → Rosenblum MG
- Stupp-Poutot G → Schalthorn A
- Sugimoto R → Yoshida T
- Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C: Intracellular concentrations of anticancer drugs in leukemic cells in vitro vs in vivo 252
- Supino R → Monti E
- Sweatman TW → Israel M
- Teicher BA → Rosbe KW
- Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS: Influence of scheduling on two-drug combinations of alkylating agents in vivo 161
- Ten Bokkel Huinink WW → Schwartzmann G
- Ten Bokkel Huinink WW → Vlasveld LT
- Thatcher N → Lind MJ
- Thomas H → Waxman J
- Tidefelt U → Sundman-Engberg B
- Tirelli U → Zanette L
- Tobias JS → Currie DC
- Tökés ZA → Aghaï E
- Tolley EA → Miller AA
- Tonini GP → Parodi MT
- Treuner J → Klingebiel T
- Trewyn RW → Gibboney DS
- Troney J → Archimbaud E
- Tutsch K → Buzaid AC
- Twelves C, Souhami R, Harper P, Goldstone A: Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation 213
- Twelves CJ, Chaudary MA, Reidy J, Richards MA, Rubens RD: Toxicity of intra-arterial doxorubicin in locally advanced breast cancer 459
- Ueland PM, Refsum H, Christensen B: Methotrexate sensitivity in Down's syndrome: a hypothesis 384
- Valenti MR → Goddard PM
- Varesio L → Parodi MT
- Vendrik CPJ → Zonnenberg BA
- Vermorken JB → Schwartzmann G
- Viala J-J → Archimbaud E
- Viar MJ → Goren MP
- Vijgh WJF van der → Schwartzmann G
- Vilmer C → Jacquillat C
- Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM, McElwain TJ: Ondansetron - a new safe and effective antiemetic in patients receiving high-dose melphalan 449
- Vlasveld LT, Beynen JH, Boogerd W, Ten Bokkel Huinink WW, Rodenhuis S: Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study 382
- Vries EGE de → Smit EF
- Wachter H → Reibnegger G
- Wagener DJT, Hoessel QGCM van, Yap SH, Hoogenraad WJ, Wobbes T, Strijk SP: Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer 131
- Wallace RE, Lindh D, Durr FE: Arabino-furanosyl-5-azacytosine: activity against human tumors in athymic mice 117
- Walsh JR → Pendyala L
- Walstad RA → Hagen B
- Wang LM, Courtland White J, Capizzi RL: The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology 418
- Watson JV → Dive C
- Waud WR → Harrison SD Jr
- Waxman J, Sandow J, Thomas H, James N, Williams G: A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer 219
- Webber S → Ferguson K
- Weil M → Jacquillat C
- Werner ER → Reibnegger G
- Werner-Felmayer G → Reibnegger G
- Whelan J → Beattie G
- White JC → Wang L-M
- Whiteley J → Ferguson K
- Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW: Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer 247
- Wilkinson PM → Lind MJ
- Wilkinson PM → Bronchud MH
- Williams CJ: A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma 304
- Williams G → Waxman J
- Winograd B → Schwartzmann G
- Wobbes T → Wagener DJT
- Wolpert-DeFilippes MK → Foster BJ
- Wootton CM → Viner CV
- Workman P → Dive C
- Xu M-J, Alberts DS, Liu R, Leibovitz A, Liu Y: In vitro evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines 89
- Yap SH → Wagener DJT
- Yin M-b → Alaoui Jamali MA
- Yoshida T, Nakamura S, Ohtake S, Kobayashi K, Kanno M, Matsuda T, Matano S, Kondo K, Okafuji K, Kanai M, Sugimoto R, Egami N, Natori H: Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, benenoyl ara-C, etoposide, and prednisolone 135
- Yuen K → Bishop JF
- Zaccheo T, Di Salle E: Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone 95
- Zalcborg J → Bishop JF
- Zanette L, Zucchetti M, Freshi A, Erranti D, Tirelli U, D'Incalci M: Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients 445
- Zimet A → Bishop JF
- Zimm S → Kirmani S
- Zonnenberg BA, Dijk A v, Vendrik CPJ, Schornagel JH, Struyvenberg A: A phase I and pharmacokinetic study using the aromatic retinoic acid analogue dichloroetretinate (Ro 12-7554) 279
- Zucchetti M → Zanette L
- Zuchowska-Vogelsang B → Pawlicki M
- Zulian GB → Viner CV
- Zunino F → Di Re F

